Sign in
KURA Stock Price, Chart, Stats & News
Kura Oncology, Inc.
Save
849.57M
Market cap
–
Current P/E
–
Forward P/E
KURA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 94.56% |
Operating margin | -449.94% |
Pretax margin | -412.51% |
Net margin | -412.95% |
Effective tax rate | -0.11% |
ROA | -37.74% |
ROE | -102.59% |
D/E | 0.12x |
Interest coverage ratio | -271.34x |
KURA valuation
P/E | – |
P/S | 10.13x |
P/B | 3.91x |
P/CF | -10.64x |
P/FCF | -9.67x |
P/OCF | -10.64x |
PEG | 0.09x |
EV multiple | -2.80x |
About
Kura Oncology, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to discovering and advancing cancer treatments within the United States. Its therapeutic portfolio primarily features small-molecule compounds engineered to combat various cancers. Among its leading drug candidates is ziftomenib, a small-molecule agent designed to disrupt the interaction of menin-Lysine K-specific Methyltransferase 2A proteins.
Similar securities
Based on sector and market capitalization
Report issue